Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer

Results from the SOCRATES retrospective study

Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, Paolo Scollo, Franco Odicino, Luigi Selvaggi, Dionyssios Katsaros, Luigi Frigerio, Liliana Mereu, Fabio Ghezzi, Luigi Manzione, Rossella Lauria, Enrico Breda, Giovanna Marforio, Michela Ballardini, Alessandra Vernaglia Lombardi, Roberto Sorio, Salvatore Tumolo, Bruno Costa, Giovanna Magni & 2 others Francesco Perrone, Giuseppe Favalli

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: It has been proposed that extending the platinum-free interval with intervening non-platinum therapy increases the efficacy of a later re-treatment with platinum in platinum-sensitive recurrent ovarian cancer. This hypothesis is based on data from small series and although it has not been validated prospectively, this strategy has entered general practice in Italy in the last years. The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005. Methods: Patients with recurrent ovarian cancer with a platinum-free interval >6 months were eligible. 493 patient files were collected and 428 were eligible and analyzed. Results: The interval from the end of the 1st line to relapse was 6-12 months in 164 patients (39.5%) and >12 months in 251 cases (60.5%). Patients received a 2nd (100%), 3rd (80.1%), 4th (50.2%), 5th (28.3%), and 6th (11.9%) line of chemotherapy. At 2nd line 282 (65.9%) received platinum (group A), while 146 (34.1%) received non-platinum chemotherapy (group B). In the latter group, 67 patients received platinum at later progression (group B1), while 79 never received platinum (group B2). Median time to platinum re-treatment was 20 and 23.1 months in patients of groups A and B1, respectively. The response rate to the first platinum received was 74.4 and 57.4% in groups A and B1, respectively (p = 0.02). Group B2 was characterized by the worst response rate and survival. At multivariate analysis time of first platinum re-treatment (2nd line vs. later; p = 0.0132; OR = 2.34) and age (p = 0.0029; OR = 2.41) was independently associated with a higher possibility of response to platinum. Conclusions: With the limits of a retrospective study, our data question the hypothesis that extending the platinum-free interval with an intervening non-platinum therapy in patients with recurrent platinum-sensitive ovarian cancer improves the response rate of a further platinum re-treatment.

Original languageEnglish
Pages (from-to)320-326
Number of pages7
JournalOncology
Volume71
Issue number5-6
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Platinum
Ovarian Neoplasms
Retrospective Studies
Therapeutics
Drug Therapy
General Practice
Italy
Multivariate Analysis
Survival Rate

Keywords

  • Chemotherapy
  • Ovarian cancer
  • Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer : Results from the SOCRATES retrospective study. / Pignata, Sandro; Ferrandina, Gabriella; Scarfone, Giovanna; Scollo, Paolo; Odicino, Franco; Selvaggi, Luigi; Katsaros, Dionyssios; Frigerio, Luigi; Mereu, Liliana; Ghezzi, Fabio; Manzione, Luigi; Lauria, Rossella; Breda, Enrico; Marforio, Giovanna; Ballardini, Michela; Vernaglia Lombardi, Alessandra; Sorio, Roberto; Tumolo, Salvatore; Costa, Bruno; Magni, Giovanna; Perrone, Francesco; Favalli, Giuseppe.

In: Oncology, Vol. 71, No. 5-6, 10.2007, p. 320-326.

Research output: Contribution to journalArticle

Pignata, S, Ferrandina, G, Scarfone, G, Scollo, P, Odicino, F, Selvaggi, L, Katsaros, D, Frigerio, L, Mereu, L, Ghezzi, F, Manzione, L, Lauria, R, Breda, E, Marforio, G, Ballardini, M, Vernaglia Lombardi, A, Sorio, R, Tumolo, S, Costa, B, Magni, G, Perrone, F & Favalli, G 2007, 'Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study', Oncology, vol. 71, no. 5-6, pp. 320-326. https://doi.org/10.1159/000108592
Pignata, Sandro ; Ferrandina, Gabriella ; Scarfone, Giovanna ; Scollo, Paolo ; Odicino, Franco ; Selvaggi, Luigi ; Katsaros, Dionyssios ; Frigerio, Luigi ; Mereu, Liliana ; Ghezzi, Fabio ; Manzione, Luigi ; Lauria, Rossella ; Breda, Enrico ; Marforio, Giovanna ; Ballardini, Michela ; Vernaglia Lombardi, Alessandra ; Sorio, Roberto ; Tumolo, Salvatore ; Costa, Bruno ; Magni, Giovanna ; Perrone, Francesco ; Favalli, Giuseppe. / Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer : Results from the SOCRATES retrospective study. In: Oncology. 2007 ; Vol. 71, No. 5-6. pp. 320-326.
@article{307d965bfda24029b65a186af15e49da,
title = "Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study",
abstract = "Background: It has been proposed that extending the platinum-free interval with intervening non-platinum therapy increases the efficacy of a later re-treatment with platinum in platinum-sensitive recurrent ovarian cancer. This hypothesis is based on data from small series and although it has not been validated prospectively, this strategy has entered general practice in Italy in the last years. The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005. Methods: Patients with recurrent ovarian cancer with a platinum-free interval >6 months were eligible. 493 patient files were collected and 428 were eligible and analyzed. Results: The interval from the end of the 1st line to relapse was 6-12 months in 164 patients (39.5{\%}) and >12 months in 251 cases (60.5{\%}). Patients received a 2nd (100{\%}), 3rd (80.1{\%}), 4th (50.2{\%}), 5th (28.3{\%}), and 6th (11.9{\%}) line of chemotherapy. At 2nd line 282 (65.9{\%}) received platinum (group A), while 146 (34.1{\%}) received non-platinum chemotherapy (group B). In the latter group, 67 patients received platinum at later progression (group B1), while 79 never received platinum (group B2). Median time to platinum re-treatment was 20 and 23.1 months in patients of groups A and B1, respectively. The response rate to the first platinum received was 74.4 and 57.4{\%} in groups A and B1, respectively (p = 0.02). Group B2 was characterized by the worst response rate and survival. At multivariate analysis time of first platinum re-treatment (2nd line vs. later; p = 0.0132; OR = 2.34) and age (p = 0.0029; OR = 2.41) was independently associated with a higher possibility of response to platinum. Conclusions: With the limits of a retrospective study, our data question the hypothesis that extending the platinum-free interval with an intervening non-platinum therapy in patients with recurrent platinum-sensitive ovarian cancer improves the response rate of a further platinum re-treatment.",
keywords = "Chemotherapy, Ovarian cancer, Recurrence",
author = "Sandro Pignata and Gabriella Ferrandina and Giovanna Scarfone and Paolo Scollo and Franco Odicino and Luigi Selvaggi and Dionyssios Katsaros and Luigi Frigerio and Liliana Mereu and Fabio Ghezzi and Luigi Manzione and Rossella Lauria and Enrico Breda and Giovanna Marforio and Michela Ballardini and {Vernaglia Lombardi}, Alessandra and Roberto Sorio and Salvatore Tumolo and Bruno Costa and Giovanna Magni and Francesco Perrone and Giuseppe Favalli",
year = "2007",
month = "10",
doi = "10.1159/000108592",
language = "English",
volume = "71",
pages = "320--326",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5-6",

}

TY - JOUR

T1 - Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer

T2 - Results from the SOCRATES retrospective study

AU - Pignata, Sandro

AU - Ferrandina, Gabriella

AU - Scarfone, Giovanna

AU - Scollo, Paolo

AU - Odicino, Franco

AU - Selvaggi, Luigi

AU - Katsaros, Dionyssios

AU - Frigerio, Luigi

AU - Mereu, Liliana

AU - Ghezzi, Fabio

AU - Manzione, Luigi

AU - Lauria, Rossella

AU - Breda, Enrico

AU - Marforio, Giovanna

AU - Ballardini, Michela

AU - Vernaglia Lombardi, Alessandra

AU - Sorio, Roberto

AU - Tumolo, Salvatore

AU - Costa, Bruno

AU - Magni, Giovanna

AU - Perrone, Francesco

AU - Favalli, Giuseppe

PY - 2007/10

Y1 - 2007/10

N2 - Background: It has been proposed that extending the platinum-free interval with intervening non-platinum therapy increases the efficacy of a later re-treatment with platinum in platinum-sensitive recurrent ovarian cancer. This hypothesis is based on data from small series and although it has not been validated prospectively, this strategy has entered general practice in Italy in the last years. The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005. Methods: Patients with recurrent ovarian cancer with a platinum-free interval >6 months were eligible. 493 patient files were collected and 428 were eligible and analyzed. Results: The interval from the end of the 1st line to relapse was 6-12 months in 164 patients (39.5%) and >12 months in 251 cases (60.5%). Patients received a 2nd (100%), 3rd (80.1%), 4th (50.2%), 5th (28.3%), and 6th (11.9%) line of chemotherapy. At 2nd line 282 (65.9%) received platinum (group A), while 146 (34.1%) received non-platinum chemotherapy (group B). In the latter group, 67 patients received platinum at later progression (group B1), while 79 never received platinum (group B2). Median time to platinum re-treatment was 20 and 23.1 months in patients of groups A and B1, respectively. The response rate to the first platinum received was 74.4 and 57.4% in groups A and B1, respectively (p = 0.02). Group B2 was characterized by the worst response rate and survival. At multivariate analysis time of first platinum re-treatment (2nd line vs. later; p = 0.0132; OR = 2.34) and age (p = 0.0029; OR = 2.41) was independently associated with a higher possibility of response to platinum. Conclusions: With the limits of a retrospective study, our data question the hypothesis that extending the platinum-free interval with an intervening non-platinum therapy in patients with recurrent platinum-sensitive ovarian cancer improves the response rate of a further platinum re-treatment.

AB - Background: It has been proposed that extending the platinum-free interval with intervening non-platinum therapy increases the efficacy of a later re-treatment with platinum in platinum-sensitive recurrent ovarian cancer. This hypothesis is based on data from small series and although it has not been validated prospectively, this strategy has entered general practice in Italy in the last years. The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005. Methods: Patients with recurrent ovarian cancer with a platinum-free interval >6 months were eligible. 493 patient files were collected and 428 were eligible and analyzed. Results: The interval from the end of the 1st line to relapse was 6-12 months in 164 patients (39.5%) and >12 months in 251 cases (60.5%). Patients received a 2nd (100%), 3rd (80.1%), 4th (50.2%), 5th (28.3%), and 6th (11.9%) line of chemotherapy. At 2nd line 282 (65.9%) received platinum (group A), while 146 (34.1%) received non-platinum chemotherapy (group B). In the latter group, 67 patients received platinum at later progression (group B1), while 79 never received platinum (group B2). Median time to platinum re-treatment was 20 and 23.1 months in patients of groups A and B1, respectively. The response rate to the first platinum received was 74.4 and 57.4% in groups A and B1, respectively (p = 0.02). Group B2 was characterized by the worst response rate and survival. At multivariate analysis time of first platinum re-treatment (2nd line vs. later; p = 0.0132; OR = 2.34) and age (p = 0.0029; OR = 2.41) was independently associated with a higher possibility of response to platinum. Conclusions: With the limits of a retrospective study, our data question the hypothesis that extending the platinum-free interval with an intervening non-platinum therapy in patients with recurrent platinum-sensitive ovarian cancer improves the response rate of a further platinum re-treatment.

KW - Chemotherapy

KW - Ovarian cancer

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=35348841132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348841132&partnerID=8YFLogxK

U2 - 10.1159/000108592

DO - 10.1159/000108592

M3 - Article

VL - 71

SP - 320

EP - 326

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5-6

ER -